Targeting proteasomes for cardioprotection

Current Opinion in Pharmacology

Volumn 9, Issue 2, 2009, Pages 167-172

  Yu, Xichun ^a   Patterson, Eugene ^a   Kem, David C ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; EPOXOMICIN; LACTACYSTIN BETA LACTONE; PROTEASOME; PROTEASOME INHIBITOR; ROSIGLITAZONE; UBIQUITIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DISEASE MODEL; DRUG MECHANISM; DRUG TARGETING; DRUG USE; ENDOTHELIAL DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE TACHYCARDIA; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; THROMBOCYTOPENIA;

ANIMALS; DRUG DELIVERY SYSTEMS; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HEART DISEASES; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 62249207273     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.11.005     Document Type: Review

References (49)

1. Ravid T., and Hochstrasser M. Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 9 (2008) 679-690
2. Mearini G., Schlossarek S., Willis M.S., and Carrier L. The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta 1782 (2008) 749-763. An extensive updated review on cardiac ubiquitin-proteasome system and its role in cardiac disease.
3. Powell S.R. The ubiquitin-proteasome system in cardiac physiology and pathology. Am J Physiol Heart Circ Physiol 291 (2006) H1-H19
4. Young G.W., Wang Y., and Ping P. Understanding proteasome assembly and regulation: importance to cardiovascular medicine. Trends Cardiovasc Med 18 (2008) 93-98
5. Gomes A.V., Young G.W., Wang Y., Zong C., Eghbali M., Drews O., Lu H., Stefani E., and Ping P. Contrasting proteome biology and functional heterogeneity of the 20S proteasome complexes in mammalian tissues. Mol Cell Proteomics 8 (2009) 302-315. First proteomic report on organ-specific responses to proteasome inhibition. Proteomic studies reveal significant heterogeneity in the structure and function of the proteasomes in the heart and liver.
6. Bulteau A.L., Lundberg K.C., Humphries K.M., Sadek H.A., Szweda P.A., Friguet B., and Szweda L.I. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 276 (2001) 30057-30063
7. Powell S.R., Wang P., Katzeff H., Shringarpure R., Teoh C., Khaliulin I., Das D.K., Davies K.J., and Schwalb H. Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome. Antioxid Redox Signal 7 (2005) 538-546
8. Ishii T., Sakurai T., Usami H., and Uchida K. Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26 S proteasome. Biochemistry 44 (2005) 13893-13901
9. Das S., Powell S.R., Wang P., Divald A., Nesaretnam K., Tosaki A., Cordis G.A., Maulik N., and Das D.K. Cardioprotection with palm tocotrienol: antioxidant activity of tocotrienol is linked with its ability to stabilize proteasomes. Am J Physiol Heart Circ Physiol 289 (2005) H361-367
10. Divald A., and Powell S.R. Proteasome mediates removal of proteins oxidized during myocardial ischemia. Free Radic Biol Med 40 (2006) 156-164
11. Farout L., Mary J., Vinh J., Szweda L.I., and Friguet B. Inactivation of the proteasome by 4-hydroxy-2-nonenal is site specific and dependent on 20S proteasome subtypes. Arch Biochem Biophys 453 (2006) 135-142
12. Gurusamy N., Goswami S., Malik G., and Das D.K. Oxidative injury induces selective rather than global inhibition of proteasomal activity. J Mol Cell Cardiol 44 (2008) 419-428. This study demonstrates that a specific rather than global proteasome inhibition occurs in the heart during ischemia/reperfusion injury.
13. Tsukamoto O., Minamino T., Okada K., Shintani Y., Takashima S., Kato H., Liao Y., Okazaki H., Asai M., Hirata A., et al. Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem Biophys Res Commun 340 (2006) 1125-1133
14. Weekes J., Morrison K., Mullen A., Wait R., Barton P., and Dunn M.J. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 3 (2003) 208-216
15. Birks E.J., Latif N., Enesa K., Folkvang T., Luong le A., Sarathchandra P., Khan M., Ovaa H., Terracciano C.M., Barton P.J., et al. Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res 79 (2008) 472-480
16. Depre C., Wang Q., Yan L., Hedhli N., Peter P., Chen L., Hong C., Hittinger L., Ghaleh B., Sadoshima J., et al. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114 (2006) 1821-1828
17. Balasubramanian S., Mani S., Shiraishi H., Johnston R.K., Yamane K., Willey C.D., Cooper G.T., Tuxworth W.J., and Kuppuswamy D. Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium is accompanied by changes in specific E3 ligases. J Mol Cell Cardiol 41 (2006) 669-679
18. Herrmann J., Soares S.M., Lerman L.O., and Lerman A. Potential role of the ubiquitin-proteasome system in atherosclerosis: aspects of a protein quality disease. J Am Coll Cardiol 51 (2008) 2003-2010
19. Herrmann J., Saguner A.M., Versari D., Peterson T.E., Chade A., Olson M., Lerman L.O., and Lerman A. Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res 101 (2007) 865-874
20. Rome S., Meugnier E., and Vidal H. The ubiquitin-proteasome pathway is a new partner for the control of insulin signaling. Curr Opin Clin Nutr Metab Care 7 (2004) 249-254
21. Balasubramanyam M., Sampathkumar R., and Mohan V. Is insulin signaling molecules misguided in diabetes for ubiquitin-proteasome mediated degradation?. Mol Cell Biochem 275 (2005) 117-125
22. Hu J., Klein J.D., Du J., and Wang X.H. Cardiac muscle protein catabolism in diabetes mellitus: activation of the ubiquitin-proteasome system by insulin deficiency. Endocrinology 149 (2008) 5384-5390. This paper describes diabetes-induced proteasomal degradation of cardiac proteins in streptozotocin-induced diabetic mice.
23. Powell S.R., Samuel S.M., Wang P., Divald A., Thirunavukkarasu M., Koneru S., Wang X., and Maulik N. Upregulation of myocardial 11S-activated proteasome in experimental hyperglycemia. J Mol Cell Cardiol 44 (2008) 618-621
24. Mao I., Liu J., Li X., and Luo H. REGgamma, a proteasome activator and beyond?. Cell Mol Life Sci 65 (2008) 3971-3980
25. Bennett M.K., and Kirk C.J. Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Dev 11 (2008) 616-625
26. Sterz J., von Metzler I., Hahne J.C., Lamottke B., Rademacher J., Heider U., Terpos E., and Sezer O. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 17 (2008) 879-895
27. Enrico O., Gabriele B., Nadia C., Sara G., Daniele V., Giulia C., Antonio S., and Mario P. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 138 (2007) 396-397
28. Hacihanefioglu A., Tarkun P., and Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 88 (2008) 219-222
29. Pye J., Ardeshirpour F., McCain A., Bellinger D.A., Merricks E., Adams J., Elliott P.J., Pien C., Fischer T.H., Baldwin Jr. A.S., et al. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 284 (2003) H919-H926
30. Stansfield W.E., Moss N.C., Willis M.S., Tang R., and Selzman C.H. Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann Thorac Surg 84 (2007) 120-125. Shows proteasome inhibition reduces infarct size, attenuates myocardial inflammatory response, and preserves regional myocardial function in a murine infarct model.
31. Yu X., Huang S., Patterson E., Garrett M.W., Kaufman K.M., Metcalf J.P., Zhu M., Dunn S.T., and Kem D.C. Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction. Am J Physiol Heart Circ Physiol 289 (2005) H1960-H1967
32. Huang S., Patterson E., Yu X., Garrett M.W., De Aos I., and Kem D.C. Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction. Am J Physiol Heart Circ Physiol 294 (2008) H1298-H1303. The authors show proteasome inhibition following myocardial ischemia suppresses fatal ventricular tachyarrhythmias, possibly by protecting against the loss of GRK2, in a canine model of myocardial infarction.
33. Jurado-Pueyo M., Campos P.M., Mayor F., and Murga C. GRK2-dependent desensitization downstream of G proteins. J Recept Signal Transduct Res 28 (2008) 59-70
34. Yu X., Zhang M., Kyker K., Patterson E., Benovic J.L., and Kem D.C. Ischemic inactivation of G protein-coupled receptor kinase and altered desensitization of canine cardiac beta-adrenergic receptors. Circulation 102 (2000) 2535-2540
35. Penela P., Ruiz-Gomez A., Castano J.G., and Mayor Jr. F. Degradation of the G protein-coupled receptor kinase 2 by the proteasome pathway. J Biol Chem 273 (1998) 35238-35244
36. Purcell N.H., Tang G., Yu C., Mercurio F., DiDonato J.A., and Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A 98 (2001) 6668-6673
37. Young D., Popovic Z.B., Jones W.K., and Gupta S. Blockade of NF-kappaB using IkappaB alpha dominant-negative mice ameliorates cardiac hypertrophy in myotrophin-overexpressed transgenic mice. J Mol Biol 381 (2008) 559-568
38. Meiners S., Dreger H., Fechner M., Bieler S., Rother W., Gunther C., Baumann G., Stangl V., and Stangl K. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 51 (2008) 302-308
39. Stansfield W.E., Tang R.H., Moss N.C., Baldwin A.S., Willis M.S., and Selzman C.H. Proteasome inhibition promotes regression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 294 (2008) H645-H650. These data demonstrate that proteasome inhibition prevents the development of hypertrophy and promotes the regression of existing hypertrophy in a murine model of agonist-induced cardiac hypertrophy.
40. Hedhli N., Lizano P., Hong C., Fritzky L.F., Dhar S.K., Liu H., Tian Y., Gao S., Madura K., Vatner S.F., et al. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol 295 (2008) H1385-H1393
41. Gao G., Zhang J., Si X., Wong J., Cheung C., McManus B., and Luo H. Proteasome inhibition attenuates coxsackievirus-induced myocardial damage in mice. Am J Physiol Heart Circ Physiol 295 (2008) H401-H408
42. Berges C., Haberstock H., Fuchs D., Miltz M., Sadeghi M., Opelz G., Daniel V., and Naujokat C. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology 124 (2008) 234-246
43. Luo H., Wu Y., Qi S., Wan X., Chen H., and Wu J. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 72 (2001) 196-202
44. Meiners S., Laule M., Rother W., Guenther C., Prauka I., Muschick P., Baumann G., Kloetzel P.M., and Stangl K. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 105 (2002) 483-489
45. Barringhaus K.G., and Matsumura M.E. The proteasome inhibitor lactacystin attenuates growth and migration of vascular smooth muscle cells and limits the response to arterial injury. Exp Clin Cardiol 12 (2007) 119-124
46. Stangl V., Lorenz M., Meiners S., Ludwig A., Bartsch C., Moobed M., Vietzke A., Kinkel H.T., Baumann G., and Stangl K. Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J 18 (2004) 272-279
47. Xu J., Wu Y., Song P., Zhang M., Wang S., and Zou M.H. Proteasome-dependent degradation of guanosine 5'-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation 116 (2007) 944-953. The authors demonstrate that diabetes induces tetrahydrobiopterin deficiency by increasing proteasome-dependent degradation of guanosine 5'-triphosphate cyclohydrolase I, a rate-limiting enzyme in the synthesis of tetrahydrobiopterin, thus causing impaired endothelial nitric oxide synthase activity and endothelial dysfunction.
48. Marfella R., D'Amico M., Di Filippo C., Baldi A., Siniscalchi M., Sasso F.C., Portoghese M., Carbonara O., Crescenzi B., Sangiuolo P., et al. Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol 47 (2006) 2444-2455
49. Marfella R., D'Amico M., Esposito K., Baldi A., Di Filippo C., Siniscalchi M., Sasso F.C., Portoghese M., Cirillo F., Cacciapuoti F., et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes 55 (2006) 622-632